Evidence map›Paper›PMID 30559131›Full record

ArticleAntimicrobial agents and chemotherapy2019

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.

Deepak V Almeida, Till F Omansen, Si-Yang Li, Jin Lee, Jacques H Grosset, Paul J Converse, Eric L Nuermberger

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Deepak V AlmeidaCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Till F OmansenCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Si-Yang LiCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Jin LeeCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Jacques H GrossetCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Paul J ConverseCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Eric L NuermbergerCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA enuermb@jhmi.edu.
Johns Hopkins University · USUniversity of Groningen · NL

Funding

Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and PreventionR01AI113266 · NIAID · JOHNS HOPKINS UNIVERSITY · PI NUERMBERGER, ERIC L · 2016 to 2020
$4.4M
NIAID NIH HHS R01 AI113266
6 · The paper itself

Abstract

Rifampin (RIF) plus clarithromycin (CLR) for 8 weeks is now the standard of care for Buruli ulcer (BU) treatment, but CLR may not be an ideal companion for rifamycins due to bidirectional drug-drug interactions. The oxazolidinone linezolid (LZD) was previously shown to be active against

Indexed as

AnimalsAnti-Bacterial AgentsBuruli UlcerClarithromycinDisease Models, AnimalFemaleLinezolidMiceMice, Inbred BALB CMycobacterium ulceransOxazolidinonesRifampinTetrazolesAnti-Bacterial AgentsClarithromycinLinezolidOxazolidinonesPNU-100480RifampintedizolidTetrazolesBuruli ulcerlinezolidMycobacterium ulceransoxazolidinonessutezolidtedizolid

Identifiers

PMID30559131
PMCPMC6395894
OpenAlexW2903964880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.